Aliskiren and amlodipine in the management of essential hypertension: meta-analysis of randomized controlled trials.
<h4>Background</h4>Aliskiren is a novel renin-angiotensin aldosterone system (RAAS) inhibitor, the combination therapy of aliskiren and amlodipine for blood pressure control have been reported recently. The primary objective of this analysis is to review recently reported randomized cont...
Main Authors: | Yukai Liu, Ken Chen, Xun Kou, Yu Han, Lin Zhou, Chunyu Zeng |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23922924/pdf/?tool=EBI |
Similar Items
-
COMPARATIVE EFFICACY OF BLOCKADE OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM WITH COMBINATIONS OF ALISKIREN AND AMLODIPINE, RAMIPRIL AND AMLODIPINE IN PATIENTS WITH ESSENTIAL HYPERTENSION
by: E. Krutikov, et al.
Published: (2017-12-01) -
Optimizing combination therapy in the management of hypertension: the role of the aliskiren, amlodipine, and hydrochlorothiazide fixed combination
by: Hovater MB, et al.
Published: (2013-06-01) -
Effects of Aliskiren Monotherapy versus Amlodipine Monotherapy in Hypertensive Patients with Obesity or Type 2 Diabetes Mellitus
by: Yasufumi Seki, et al.
Published: (2023-10-01) -
A systematic review and meta-analysis of aliskiren and angiotension receptor blockers in the management of essential hypertension
by: Zhenfeng Zheng, et al.
Published: (2011-06-01) -
Renin inhibition with aliskiren in hypertension: focus on aliskiren/hydrochlorothiazide combination therapy
by: Kalathil K Sureshkumar
Published: (2008-12-01)